Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $1.7 million.

  • Maxcyte's Other Non Operating Income fell 3056.89% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 2547.86%. This contributed to the annual value of $10.1 million for FY2024, which is 225.52% down from last year.
  • According to the latest figures from Q3 2025, Maxcyte's Other Non Operating Income is $1.7 million, which was down 3056.89% from $1.9 million recorded in Q2 2025.
  • Maxcyte's Other Non Operating Income's 5-year high stood at $2.8 million during Q4 2023, with a 5-year trough of -$732500.0 in Q1 2021.
  • Its 5-year average for Other Non Operating Income is $1.5 million, with a median of $1.9 million in 2022.
  • As far as peak fluctuations go, Maxcyte's Other Non Operating Income skyrocketed by 1050652.17% in 2022, and later tumbled by 3056.89% in 2025.
  • Over the past 5 years, Maxcyte's Other Non Operating Income (Quarter) stood at $80800.0 in 2021, then soared by 2302.35% to $1.9 million in 2022, then soared by 45.18% to $2.8 million in 2023, then fell by 18.24% to $2.3 million in 2024, then fell by 24.78% to $1.7 million in 2025.
  • Its Other Non Operating Income was $1.7 million in Q3 2025, compared to $1.9 million in Q2 2025 and $2.0 million in Q1 2025.